- Home
- HOLO vs LSB Comparison
HOLO vs LSB Comparison
Compare HOLO & LSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOLO
- LSB
- Stock Information
- Founded
- HOLO 2018
- LSB 2002
- Country
- HOLO China
- LSB China
- Employees
- HOLO N/A
- LSB N/A
- Industry
- HOLO Computer Software: Programming Data Processing
- LSB
- Sector
- HOLO Technology
- LSB
- Exchange
- HOLO Nasdaq
- LSB NYSE
- Market Cap
- HOLO 24.9M
- LSB 22.3M
- IPO Year
- HOLO N/A
- LSB N/A
- Fundamental
- Price
- HOLO $4.87
- LSB $0.94
- Analyst Decision
- HOLO
- LSB
- Analyst Count
- HOLO 0
- LSB 0
- Target Price
- HOLO N/A
- LSB N/A
- AVG Volume (30 Days)
- HOLO 3.5M
- LSB 21.6K
- Earning Date
- HOLO 01-01-0001
- LSB 07-07-2025
- Dividend Yield
- HOLO N/A
- LSB N/A
- EPS Growth
- HOLO N/A
- LSB N/A
- EPS
- HOLO N/A
- LSB N/A
- Revenue
- HOLO $39,771,750.00
- LSB $79,415,311.00
- Revenue This Year
- HOLO N/A
- LSB $39.33
- Revenue Next Year
- HOLO N/A
- LSB $75.61
- P/E Ratio
- HOLO N/A
- LSB N/A
- Revenue Growth
- HOLO 42.62
- LSB N/A
- 52 Week Low
- HOLO $4.16
- LSB $0.36
- 52 Week High
- HOLO $848.00
- LSB $6.82
- Technical
- Relative Strength Index (RSI)
- HOLO 41.35
- LSB 37.29
- Support Level
- HOLO $4.40
- LSB $0.91
- Resistance Level
- HOLO $5.22
- LSB $1.03
- Average True Range (ATR)
- HOLO 0.38
- LSB 0.06
- MACD
- HOLO 0.39
- LSB 0.01
- Stochastic Oscillator
- HOLO 78.30
- LSB 43.75
About HOLO MicroCloud Hologram Inc.
MicroCloud Hologram Inc, through its subsidiaries, is mainly engaged in holographic Technology. It includes Holographic solutions and Holographic technology services. The company also provides holographic digital twin technology services for customers and has built a holographic digital twin technology resource library. Geographically company is operating in single segment, China.
About LSB LAKESHORE BIOPHARMA CO LTD
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.